Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.36 |
| ▸ | LMNA | P02545 | 3/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | KCNA5 | P22460 | 3/20 | 0.33 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.33 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.33 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.33 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.32 |
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18228601 | 0.93 | KDM4E (0.38) | KDM4EUSP2POLBALDH1A1LMNA | |
| SCHEMBL3116626 | 0.78 | PLD1 (0.46) | KDM4EUSP2ALDH1A1MAPTKCNA5 | |
| SCHEMBL6984667 | 0.72 | KDM4E (0.36) | KDM4EUSP2POLBALDH1A1LMNA | |
| SCHEMBL18228035 | 0.72 | GAA (0.32) | GAAHTTSORD | |
| SCHEMBL9984447 | 0.71 | PLD1 (0.47) | KDM4EUSP2ALDH1A1MAPTKCNA5 | |
| SCHEMBL207223 | 0.70 | CHKA (0.56) | ALDH1A1LMNAMAPTTDP1CYP2D6 | |
| SCHEMBL2646639 | 0.69 | SORD (0.40) | KDM4EALDH1A1LMNASORD | |
| SCHEMBL18228600 | 0.69 | KDM4E (0.60) | KDM4EUSP2POLBALDH1A1LMNA | |
| SCHEMBL3339822 | 0.69 | KDM4E (0.60) | KDM4EUSP2POLBALDH1A1LMNA | |
| SCHEMBL1928132 | 0.67 | KDM4E (0.58) | KDM4EUSP2POLBALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180148429-A1 | SUBSTITUTED QUINOXALINE DERIVATIVES | SELVITA S.A. (PL) | 2018-05-31 | — | — | US | claimed |
| EP-3294729-A1 | SUBSTITUTED QUINOXALINE DERIVATIVES | SELVITA S.A. (PL) | 2018-03-21 | — | — | EP | claimed |
| WO-2016180536-A1 | SUBSTITUTED QUINOXALINE DERIVATIVES | SELVITA S.A. (PL) | 2016-11-17 | — | — | WO | claimed |
| EP-2368889-A1 | Inhibitors of tyrosine kinases | Novartis AG (CH) | 2011-09-28 | — | — | EP | claimed |
| US-20110218187-A1 | INHIBITORS OF TYROSINE KINASES | BREITENSTEIN WERNER | 2011-09-08 | — | — | US | claimed |
| EP-2357182-A1 | Inhibitors of tyrosine kinases | Novartis AG (CH) | 2011-08-17 | — | — | EP | claimed |
| US-7956053-B2 | Inhibitors of tyrosine kinases | NOVARTIS AG (CH) | 2011-06-07 | — | — | US | claimed |
| EP-2100891-A1 | Inhibitors of tyrosine kinases | Novartis AG (CH) | 2009-09-16 | — | — | EP | claimed |
| US-20070093506-A1 | Inhibitors of tyrosine kinases | BREITENSTEIN WERNER | 2007-04-26 | — | — | US | claimed |
| US-20060167015-A1 | 4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-N-[5-(4-methyl-1H-imidazol1yl)-3-(trifluoromethyl)phenyl]benzamide or an N-oxide or salts; anticarcinogenic agent (leukaemia) | NOVARTIS AG (CH) | 2006-07-27 | — | — | US | claimed |
| EP-1532138-A1 | INHIBITORS OF TYROSINE KINASES | Novartis AG (CH) | 2005-05-25 | — | — | EP | claimed |
| WO-2004005281-A1 | INHIBITORS OF TYROSINE KINASES | NOVARTIS AG (CH) | 2004-01-15 | — | — | WO | claimed |
| US-20180148429-A1 | SUBSTITUTED QUINOXALINE DERIVATIVES | SELVITA S.A. (PL) | 2018-05-31 | — | — | US | disclosed |
| EP-3294729-A1 | SUBSTITUTED QUINOXALINE DERIVATIVES | SELVITA S.A. (PL) | 2018-03-21 | — | — | EP | disclosed |
| WO-2016180536-A1 | SUBSTITUTED QUINOXALINE DERIVATIVES | SELVITA S.A. (PL) | 2016-11-17 | — | — | WO | disclosed |
| EP-2368889-A1 | Inhibitors of tyrosine kinases | Novartis AG (CH) | 2011-09-28 | — | — | EP | disclosed |
| US-7169791-B2 | Inhibitors of tyrosine kinases | NOVARTIS AG (CH) | 2007-01-30 | — | — | US | disclosed |
| US-20060167015-A1 | 4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-N-[5-(4-methyl-1H-imidazol1yl)-3-(trifluoromethyl)phenyl]benzamide or an N-oxide or salts; anticarcinogenic agent (leukaemia) | NOVARTIS AG (CH) | 2006-07-27 | — | — | US | disclosed |
| EP-1532138-A1 | INHIBITORS OF TYROSINE KINASES | Novartis AG (CH) | 2005-05-25 | — | — | EP | disclosed |
| WO-2004005281-A1 | INHIBITORS OF TYROSINE KINASES | NOVARTIS AG (CH) | 2004-01-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070093506-A1 | Inhibitors of tyrosine kinases | ABL1, BTK, FLT3 | KDM4E 519/4885USP2 3017/4885POLB 2751/4885 |
| US-20110218187-A1 | INHIBITORS OF TYROSINE KINASES | ABL1, BTK, FLT3 | KDM4E 519/4885USP2 3017/4885POLB 2751/4885 |
| US-20060167015-A1 | 4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-N-[5-(4-methyl-1H-imidazol1yl)-3-(trifluoromethyl)phenyl]benzamide or an N-oxide or salts; anticarcinogenic agent (leukaemia) | ABL1, CDK2, CDKN1A | KDM4E 445/4885USP2 4110/4885POLB 1386/4885 |
| US-20180148429-A1 | SUBSTITUTED QUINOXALINE DERIVATIVES | BRCA1, NQO2, NQO1 | KDM4E 1664/4885USP2 2344/4885POLB 387/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.